<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097265</url>
  </required_header>
  <id_info>
    <org_study_id>JBZ-EnRoute+</org_study_id>
    <secondary_id>CDR0000668525</secondary_id>
    <secondary_id>EUDRACT-2010-018612-32</secondary_id>
    <secondary_id>EU-21016</secondary_id>
    <nct_id>NCT01097265</nct_id>
  </id_info>
  <brief_title>Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>The Influence of Micrometastases on Prognosis and Survival in Stage I-II Colon Cancer Patients: The EnRoute+ Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeroen Bosch Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures such as sentinel lymph node mapping may help doctors find
      patients who are at risk of developing micrometastases and plan better treatment.

      PURPOSE: This randomized phase II/III trial is studying micrometastases in patients with
      stage I or stage II localized colon cancer that can be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the subset of patients with stage I or II localized, resectable colon
           cancer (pN0) at risk for developing systemic metastases.

        -  To determine the clinical and prognostic relevance of occult nodal isolated tumor cells
           and micrometastases in these patients.

        -  To determine the benefits of adjuvant chemotherapy in patients with pN0micro+ colon
           cancer.

      OUTLINE: This is a phase II feasibility study (stage 1) followed by a phase III multicenter,
      open-label, randomized, and controlled study (stage 2).

        -  Stage 1 (phase II feasibility study) After undergoing planned curative resection
           followed by ex vivo sentinel lymph node mapping (SLNM). Resected samples are examined.
           The sentinel lymph nodes of those deemed pN0 disease (no macroscopic metastases or
           angioinvasion) are further evaluated for micrometastases by serial sectioning and
           immunohistochemistry using pan-cytokeratin. pN0micro+ disease are defined as isolated
           tumor cells (ITC) &lt; 0.2 mm or micrometastasis 0.2 - 2 mm. Patients with pN0 disease are
           followed-up once every 6 months for 3 years and then annually for 2 years.

        -  stage 2 (phase III randomized study): Patients undergo planned surgery and ex vivo SLNM
           as in stage 1. Patients with pN0micro- disease are assigned to arm C; patients with
           pN0micro+ disease are randomized to 1 of 2 intervention arms (arms A and B). .

             -  Arm A (pN0micro+): Patients receive oral capecitabine twice daily on days 1-14 and
                oxaliplatin IV over 2 hours on day 1 OR oral capecitabine twice daily on days 1-14
                alone according to standard protocol. Treatment repeats every 4 weeks for up to 8
                courses. Patients are followed-up once every 6 months for 3 years and then annually
                for 2 years.

             -  Arm B (pN0micro+): Patients are followed-up once every 6 months for 3 years and
                then annually for 2 years.

             -  Arm C (pN0micro-): Patients are followed-up once every 6 months for 3 years and
                then annually for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accrual rate (total number of pN0 patients included in the registration study monthly/center) (stage 1)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of upstaging in pN0 colon cancer patients (stage 1)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival (DFS) at 3 years (stage 2)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of successful sentinel lymph node mapping procedures using multivariate analysis (stage 2)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) at 3 years (stage 2)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stratified analysis of DFS and OS according to total harvested lymph nodes per resected specimen and chemotherapy regimen (capecitabine and oxaliplatin versus capecitabine alone) (stage 2)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>active surveillance</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymph node mapping</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or radiologically confirmed primary colon cancer

               -  Stage I or II disease

          -  Clinically localized disease judged potentially resectable for cure, without
             intraoperatively gross nodal involvement

          -  Planning to undergo elective resection of the tumor

          -  No histologically or radiologically confirmed locoregional lymph node or distant
             metastasis

          -  No disseminated disease

          -  No clinical tumor perforation or obstruction

          -  Patients enrolled in stage 2 and undergoing randomization must also meet the following
             criteria:

               -  pN0micro+ disease as evidenced by detection of sentinel lymph node isolated tumor
                  cells (&lt;0.2 mm) or micrometastasis (0.2 - 2 mm)

               -  No high-risk pN0 disease meeting any of the following criteria:

                    -  Less then 10 lymph nodes detected in resected specimen

                    -  Invasion in other organs (T4, Nx, Mx)

                    -  Colon perforation at presentation

                    -  Obstruction at presentation

                    -  Angioinvasion at pathological examination

               -  No rectal cancer

               -  No clinically positive nodal tumors or advanced disease (stage III or Dukes stage
                  C disease)

        PATIENT CHARACTERISTICS:

          -  Patients enrolled in stage 2 and undergoing randomization must also meet the following
             criteria:

               -  WHO performance status 0-1 or American Society of Anesthesiologists Physical
                  Status classification 1-2

               -  Not pregnant or nursing

               -  Able to comply with requirements of the study

               -  Must be fit to undergo chemotherapy treatment

               -  No other current serious illness or medical conditions, including any of the
                  following:

                    -  Severe cardiac illness (NYHA class III-IV disease)

                    -  Significant neurologic or psychiatric disorders

                    -  Uncontrolled infections

                    -  Active disseminated intravascular coagulation

                    -  Other serious underlying medical conditions that could impair the ability of
                       the patient to participate in the study

               -  No known hypersensitivity to study drugs

               -  No definite contraindications for the use of corticosteroids

        PRIOR CONCURRENT THERAPY:

          -  No prior colorectal surgery

          -  Patients enrolled in stage 2 and undergoing randomization must also meet the following
             criteria:

               -  No prior chemotherapy (for patients enrolled in stage 2 and undergoing
                  randomization only)

               -  At least 4 weeks since prior and no other concurrent experimental drugs

               -  No concurrent immunosuppressive or antiviral drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koop Bosscha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeroen Bosch Ziekenhuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-73-699-2701</phone>
      <email>k.bosscha@jbz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-20-444-4300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 BE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-20-512-9111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-20-566-9111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-40-239-9111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-50-361-2317</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-71-526-2309</phone>
      <email>c.j.h.van_de_velde@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-43-387-7025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-24-361-0353</phone>
      <email>c.punt@onco.umcn.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Rotterdam at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-10-463-5995</phone>
      <email>w.r.schouten@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-30-250-9111</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Lips DJ, Koebrugge B, Liefers GJ, van de Linden JC, Smit VT, Pruijt HF, Putter H, van de Velde CJ, Bosscha K. The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute⊕ Study. BMC Surg. 2011 May 11;11:11. doi: 10.1186/1471-2482-11-11.</citation>
    <PMID>21569373</PMID>
  </results_reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Micrometastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

